Impact of time to appropriate therapy on mortality in patients with vancomycin-intermediate Staphylococcus aureus infection

Keyphrases

• Time-to-treatment 100%
• Staphylococcal Infections 100%
• Time Impact 100%
• Vancomycin-intermediate Staphylococcus Aureus 100%
• Methicillin-resistant S. Aureus 41%
• Prudent Antimicrobial Use 25%
• Logistic Regression Analysis 16%
• Health Assessment 16%
• Chronic Conditions 16%
• Acute Physiology 16%
• Excess Mortality 16%
• Site Infection 16%
• Pneumonia 8%
• Retrospective Cohort Study 8%
• Clinical Outcomes 8%
• Odds Ratio 8%
• Number of Patients 8%
• Increased Incidence 8%
• Vancomycin 8%
• Staphylococcus Aureus 8%
• Critically Ill Patients 8%
• Antibiotic Therapy 8%
• Single Center 8%
• All-cause Mortality 8%
• Kaplan-Meier Curve 8%
• Antimicrobial Therapy 8%
• Non-survivors 8%
• Linezolid 8%
• Infection Process 8%
• Unknown Source 8%
• Solid Organ Malignancy 8%
• S. Aureus Infection 8%
• Comorbidity Treatment 8%
• Classification Treatment 8%
• Skilled Care Facility 8%

Nursing and Health Professions

• Vancomycin 100%
• Staphylococcus Infection 100%
• Meticillin 38%
• Infection 30%
• Antimicrobial Therapy 30%
• Multivariate Logistic Regression Analysis 15%
• APACHE 15%
• Mortality 15%
• Odds Ratio 7%
• Cohort Analysis 7%
• Clinical Outcome 7%
• Antibiotic Therapy 7%
• All Cause Mortality 7%
• Kaplan Meier Method 7%
• Linezolid 7%
• Subacute Care 7%
• Comorbidity 7%

Immunology and Microbiology

• Vancomycin Intermediate Staphylococcus Aureus 100%
• Staphylococcus Aureus 50%
• Mortality 16%
• All Cause Mortality 8%
• Comorbidity 8%